RBC Capital Markets’s $37 target on ACAD

ACAD Acadia Pharmaceuticals Inc

$20.1 → $37 (+84%) by Oct 2027

Outperform · reiterates · said Oct 5, 2026 · 12-month default horizon

Open: judged on the close on Oct 5, 2027

The article this target came from

RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments

Investing.com · Oct 5, 2026

RBC Capital maintained its Outperform rating on Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) with a $37.00 price target.

RBC Capital Markets’s track record → Acadia Pharmaceuticals Inc →

A fact about what RBC Capital Markets published, as reported by Investing.com, not a recommendation from Dalsna Finance; RBC Capital Markets is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.